Free Trial
→ Here’s How to Claim Your Stake in Elon’s Private Company, xAI (From Brownstone Research) (Ad) Buy CRSP Stock  Free CRSP Stock Alerts

CRISPR Therapeutics (CRSP) Financials

CRISPR Therapeutics logo
$37.62 -0.63 (-1.65%)
Closing price 04:00 PM Eastern
Extended Trading
$37.78 +0.16 (+0.41%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for CRISPR Therapeutics

Annual Income Statements for CRISPR Therapeutics

This table shows CRISPR Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -26 -23 -68 -165 67 -349 373 -650 -154 -366
Consolidated Net Income / (Loss)		 -26 -23 -68 -165 67 -349 378 -650 -154 -366
Net Income / (Loss) Continuing Operations		 -26 -23 -68 -165 67 -349 378 -650 -154 -366
Total Pre-Tax Income 		-26 -23 -67 -164 67 -348 380 -651 -151 -363
Total Operating Income		 -26 -68 -65 -159 47 -354 374 -673 -223 -467
Total Gross Profit		 0.25 5.16 41 3.12 290 0.72 915 1.20 371 37
Total Revenue		 0.25 5.16 41 3.12 290 0.72 915 1.20 371 37
Operating Revenue		 0.25 5.16 41 3.12 290 0.72 915 1.20 371 37
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 26 73 106 162 243 355 541 674 594 504
Selling, General & Admin Expense		 13 31 36 48 63 86 100 102 76 73
Research & Development Expense		 13 42 70 114 179 221 341 462 387 321
Other Operating Expenses / (Income)		 - - - - - 48 101 110 130 110
Total Other Income / (Expense), net		 -0.09 45 -1.96 -5.49 21 6.38 6.00 23 72 104
Other Income / (Expense), net		 0.02 79 -0.20 -1.21 26 6.38 6.00 23 72 104
Income Tax Expense		 0.01 0.48 1.75 0.55 0.45 0.81 1.87 -0.33 2.89 3.59
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.01 0.02 -0.04 0.02 -0.02 -0.04 4.98 0.08 -0.07 0.07
Basic Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $1.23 ($5.29) $4.97 ($8.36) ($1.94) ($4.34)
Weighted Average Basic Shares Outstanding		 5.04M 12.26M 40.06M 47.96M 54.39M 65.95M 75.95M 77.75M 79.22M 84.36M
Diluted Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $1.17 ($5.29) $4.70 ($8.36) ($1.94) ($4.34)
Weighted Average Diluted Shares Outstanding		 5.04M 12.26M 40.06M 47.96M 56.93M 65.95M 80.39M 77.75M 79.22M 84.36M
Weighted Average Basic & Diluted Shares Outstanding		 5.04M 12.26M 40.06M 47.96M 60.85M 75.43M 77.07M 78.65M 80.28M 85.77M

Quarterly Income Statements for CRISPR Therapeutics

This table shows CRISPR Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -176 -105 -53 -78 -112 89 -120 -126 -86 -34
Consolidated Net Income / (Loss)		 -175 -111 -53 -78 -112 89 -117 -126 -86 -37
Net Income / (Loss) Continuing Operations		 -175 -111 -53 -78 -112 89 -117 -126 -86 -37
Total Pre-Tax Income 		-175 -120 -52 -77 -112 90 -116 -125 -85 -37
Total Operating Income		 -182 -132 -64 -95 -132 70 -141 -151 -110 -65
Total Gross Profit		 0.09 0.01 100 70 0.00 201 0.50 0.52 0.60 36
Total Revenue		 0.09 0.01 100 70 0.00 201 0.50 0.52 0.60 36
Operating Revenue		 0.09 0.01 100 70 0.00 201 0.50 0.52 0.60 36
Total Operating Expenses		 182 132 164 165 132 132 141 152 111 100
Selling, General & Admin Expense		 27 21 22 19 18 16 18 19 17 18
Research & Development Expense		 117 104 100 102 91 95 76 80 82 82
Total Other Income / (Expense), net		 7.26 11 13 18 21 20 25 26 25 28
Other Income / (Expense), net		 7.26 11 13 18 21 20 25 26 25 28
Income Tax Expense		 -0.58 -9.48 1.32 0.92 0.41 0.23 0.72 1.29 0.88 0.70
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 1.92 -5.32 -0.03 -0.03 0.05 -0.06 3.47 -0.00 -0.08 -3.31
Basic Earnings per Share		 ($2.24) ($1.40) ($0.67) ($0.98) ($1.41) $1.12 ($1.43) ($1.49) ($1.01) ($0.41)
Weighted Average Basic Shares Outstanding		 78.02M 77.75M 78.68M 79.09M 79.41M 79.22M 81.79M 84.92M 85.23M 84.36M
Diluted Earnings per Share		 ($2.24) ($1.40) ($0.67) ($0.98) ($1.41) $1.12 ($1.43) ($1.49) ($1.01) ($0.41)
Weighted Average Diluted Shares Outstanding		 78.02M 77.75M 78.68M 79.09M 79.41M 79.22M 81.79M 84.92M 85.23M 84.36M
Weighted Average Basic & Diluted Shares Outstanding		 78.29M 78.65M 78.94M 79.41M 79.43M 80.28M 84.92M 85.17M 85.35M 85.77M

Annual Cash Flow Statements for CRISPR Therapeutics

This table details how cash moves in and out of CRISPR Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 155 162 -76 217 489 237 -246 -716 177 -91
Net Cash From Operating Activities		 59 -53 -70 -96 57 -238 539 -496 -260 -143
Net Cash From Continuing Operating Activities		 59 -53 -70 -96 57 -238 539 -496 -260 -143
Net Income / (Loss) Continuing Operations		 -26 -23 -68 -165 67 -349 378 -650 -154 -366
Consolidated Net Income / (Loss)		 -26 -23 -68 -165 67 -349 378 -650 -154 -366
Depreciation Expense		 0.13 0.93 3.02 3.52 4.73 9.18 18 24 20 19
Non-Cash Adjustments To Reconcile Net Income		 3.11 -35 21 55 34 68 116 110 67 48
Changes in Operating Assets and Liabilities, net		 82 4.23 -25 11 -48 33 27 20 -194 156
Net Cash From Investing Activities		 -1.15 32 -8.31 -2.77 1.33 -541 -1,035 -259 375 -280
Net Cash From Continuing Investing Activities		 -1.15 32 -8.31 -2.77 1.33 -541 -1,035 -259 375 -280
Purchase of Property, Plant & Equipment		 -1.15 -3.02 -7.81 -2.77 -6.68 -18 -82 -37 -9.47 -1.90
Acquisitions		 - -0.10 - - 8.01 - 0.00 0.00 -2.50 0.00
Purchase of Investments		 - - -0.50 0.00 0.00 -594 -1,509 -1,418 -1,066 -1,486
Sale and/or Maturity of Investments		 - - - 0.00 0.00 71 556 1,196 1,453 1,208
Net Cash From Financing Activities		 97 183 2.61 316 431 1,016 251 39 63 332
Net Cash From Continuing Financing Activities		 97 183 2.61 316 431 1,016 251 39 63 332
Issuance of Common Equity		 - 89 - 316 431 1,016 251 39 63 332
Effect of Exchange Rate Changes		 0.01 - - - 0.02 0.04 -0.01 -0.08 0.07 -0.02

Quarterly Cash Flow Statements for CRISPR Therapeutics

This table details how cash moves in and out of CRISPR Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -2.74 -286 132 100 83 -139 318 -223 -259 73
Net Cash From Operating Activities		 -105 -113 8.80 -133 -40 -96 110 -96 -107 -50
Net Cash From Continuing Operating Activities		 -105 -113 8.80 -133 -40 -96 110 -96 -107 -50
Net Income / (Loss) Continuing Operations		 -175 -111 -53 -78 -112 89 -117 -126 -86 -37
Consolidated Net Income / (Loss)		 -175 -111 -53 -78 -112 89 -117 -126 -86 -37
Depreciation Expense		 5.02 5.85 5.05 4.96 4.93 4.90 4.83 4.85 4.74 4.84
Non-Cash Adjustments To Reconcile Net Income		 27 23 20 19 15 14 11 15 15 6.79
Changes in Operating Assets and Liabilities, net		 37 -32 37 -79 53 -204 210 10 -40 -24
Net Cash From Investing Activities		 87 -176 118 217 121 -81 -98 -127 -162 106
Net Cash From Continuing Investing Activities		 87 -176 118 217 121 -81 -98 -127 -162 106
Purchase of Property, Plant & Equipment		 -6.02 -6.19 -3.06 -3.56 -2.12 -0.74 -0.72 -0.71 -0.22 -0.25
Purchase of Investments		 -326 -494 -266 -187 -245 -368 -334 -476 -409 -267
Sale and/or Maturity of Investments		 420 325 387 409 370 287 237 350 248 373
Net Cash From Financing Activities		 15 2.48 5.40 17 1.56 39 306 -0.47 9.64 17
Net Cash From Continuing Financing Activities		 15 2.48 5.40 17 1.56 39 306 -0.47 9.64 17
Issuance of Common Equity		 15 2.48 5.40 17 1.56 39 306 -0.47 9.64 17
Effect of Exchange Rate Changes		 -0.10 0.12 0.03 0.03 -0.05 0.06 -0.01 0.00 0.08 -0.09

Annual Balance Sheets for CRISPR Therapeutics

This table presents CRISPR Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 159 345 271 489 1,067 1,828 2,752 2,243 2,230 2,242
Total Current Assets		 157 320 248 466 988 1,717 2,418 1,853 1,908 1,937
Cash & Equivalents		 156 316 240 457 944 1,169 923 212 389 298
Short-Term Investments		 - - - - 0.00 522 1,456 1,603 1,304 1,606
Accounts Receivable		 0.34 3.16 2.63 0.09 0.10 0.14 0.31 0.00 200 25
Prepaid Expenses		 0.54 1.51 6.00 9.66 44 26 38 38 14 8.31
Plant, Property, & Equipment, net		 1.33 21 19 19 31 42 138 164 152 134
Total Noncurrent Assets		 1.26 3.75 4.10 4.12 48 69 197 226 170 171
Long-Term Investments		 - - - - - - 0.00 53 1.97 0.00
Intangible Assets		 0.45 0.40 0.34 0.29 0.24 0.18 0.13 0.07 0.02 0.00
Other Noncurrent Operating Assets		 0.10 0.20 0.61 3.83 48 69 197 173 168 171
Total Liabilities & Shareholders' Equity		 159 345 271 489 1,067 1,828 2,752 2,243 2,230 2,242
Total Liabilities		 124 112 84 97 127 164 352 368 347 310
Total Current Liabilities		 10 22 15 28 57 94 120 121 109 88
Accounts Payable		 1.58 4.57 1.64 5.07 5.94 9.09 15 27 38 15
Accrued Expenses		 8.43 16 11 21 30 54 91 78 45 41
Current Deferred Revenue		 0.00 1.03 1.03 1.30 0.96 2.34 1.01 0.00 4.11 3.85
Current Deferred & Payable Income Tax Liabilities		 0.08 0.02 0.35 0.40 0.58 10 0.72 0.14 0.44 0.45
Other Current Liabilities		 0.06 0.06 0.14 0.12 19 19 12 16 21 28
Total Noncurrent Liabilities		 114 90 69 69 70 69 233 246 238 222
Noncurrent Deferred Revenue		 75 90 69 69 12 12 12 12 14 12
Other Noncurrent Operating Liabilities		 0.28 0.19 0.31 0.24 58 58 220 234 224 210
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -29 233 188 392 939 1,664 2,399 1,875 1,883 1,932
Total Preferred & Common Equity		 -29 233 188 392 939 1,664 2,399 1,875 1,883 1,932
Total Common Equity		 -29 233 188 392 939 1,664 2,399 1,875 1,883 1,932
Common Stock		 4.82 290 313 684 1,164 2,238 2,601 2,737 2,881 3,296
Retained Earnings		 -34 -57 -125 -292 -225 -574 -196 -846 -1,000 -1,366
Treasury Stock		 0.00 0.00 0.00 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06
Accumulated Other Comprehensive Income / (Loss)		 -0.01 -0.03 0.01 -0.01 0.01 -0.08 -5.07 -16 1.91 1.84

Quarterly Balance Sheets for CRISPR Therapeutics

This table presents CRISPR Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 2,353 2,244 2,197 2,087 2,439 2,340 2,256
Total Current Assets		 1,933 1,908 1,860 1,761 2,120 2,010 1,944
Cash & Equivalents		 494 344 445 528 707 484 226
Short-Term Investments		 1,402 1,539 1,323 1,212 1,401 1,517 1,710
Accounts Receivable		 0.05 0.00 70 0.00 0.00 0.00 0.00
Prepaid Expenses		 37 25 21 21 11 8.79 8.25
Plant, Property, & Equipment, net		 166 162 159 156 147 143 139
Total Noncurrent Assets		 255 174 178 170 172 186 174
Long-Term Investments		 77 6.32 4.90 0.00 0.00 11 0.00
Intangible Assets		 0.08 0.06 0.04 0.03 0.00 0.00 0.00
Other Noncurrent Operating Assets		 177 168 173 170 172 175 174
Total Liabilities & Shareholders' Equity		 2,353 2,244 2,197 2,087 2,439 2,340 2,256
Total Liabilities		 399 389 381 359 355 359 316
Total Current Liabilities		 151 147 133 111 119 128 90
Accounts Payable		 32 45 28 26 16 9.45 16
Accrued Expenses		 103 86 90 66 76 92 47
Current Deferred Revenue		 0.00 0.00 0.00 3.50 4.07 4.76 4.48
Current Deferred & Payable Income Tax Liabilities		 4.27 0.27 0.56 0.18 1.21 0.45 0.84
Other Current Liabilities		 12 16 15 15 21 21 22
Total Noncurrent Liabilities		 249 243 248 248 236 231 227
Noncurrent Deferred Revenue		 12 12 12 16 14 13 12
Other Noncurrent Operating Liabilities		 236 230 236 232 223 218 214
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,954 1,855 1,816 1,728 2,084 1,981 1,940
Total Preferred & Common Equity		 1,954 1,855 1,816 1,728 2,084 1,981 1,940
Total Common Equity		 1,954 1,855 1,816 1,728 2,084 1,981 1,940
Common Stock		 2,712 2,764 2,802 2,824 3,202 3,227 3,258
Retained Earnings		 -736 -899 -977 -1,089 -1,116 -1,243 -1,329
Treasury Stock		 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06
Accumulated Other Comprehensive Income / (Loss)		 -22 -9.39 -8.91 -6.80 -1.55 -2.88 11

Annual Metrics and Ratios for CRISPR Therapeutics

This table displays calculated financial ratios and metrics derived from CRISPR Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 1,990.69% 693.90% -92.38% 9,169.85% -99.75% 127,154.94% -99.87% 30,885.48% -89.95%
EBITDA Growth		 -274.89% 144.19% -646.75% -153.37% 149.48% -537.27% 217.30% -257.57% 79.10% -162.37%
EBIT Growth		 -274.66% 140.38% -724.59% -146.98% 145.44% -578.28% 209.04% -271.40% 76.83% -140.62%
NOPAT Growth		 -288.25% -164.80% 5.11% -145.86% 141.73% -634.38% 249.81% -226.78% 66.94% -109.66%
Net Income Growth		 -87.04% 10.17% -194.62% -141.35% 140.52% -621.80% 208.25% -272.16% 76.37% -138.43%
EPS Growth		 -356.85% 62.65% 9.52% -101.17% 134.01% -552.14% 188.85% -277.87% 76.79% -123.71%
Operating Cash Flow Growth		 1,339.89% -188.95% -32.60% -37.30% 158.89% -520.57% 326.11% -191.98% 47.48% 45.17%
Free Cash Flow Firm Growth		 0.00% -169.00% -69.66% -34.06% 86.57% -1,554.72% 243.70% -240.78% 26.65% 50.07%
Invested Capital Growth		 0.00% -3.49% 35.82% -17.02% 93.26% -500.53% 177.90% -65.42% 2,561.61% -84.90%
Revenue Q/Q Growth		 0.00% 0.00% 272.16% -91.16% 36.16% -99.07% 1.39% -91.50% 118.35% -81.60%
EBITDA Q/Q Growth		 0.00% 0.00% -525.40% -43.15% 60,445.31% -67.53% -7.58% 3.55% 61.46% -58.14%
EBIT Q/Q Growth		 0.00% 0.00% -418.14% -41.98% 1,870.63% -65.49% -8.73% 3.48% 58.17% -53.36%
NOPAT Q/Q Growth		 0.00% 0.00% 28.90% -40.98% 800.32% -50.38% -8.80% 2.06% 47.47% -40.37%
Net Income Q/Q Growth		 0.00% 0.00% -32.99% -40.71% 693.03% -65.12% -8.31% 4.51% 56.55% -52.86%
EPS Q/Q Growth		 0.00% 0.00% -144.53% -37.60% 348.94% -72.88% -0.84% 1.88% 56.50% -54.45%
Operating Cash Flow Q/Q Growth		 0.00% -259.65% 2.94% -16.36% 127.35% -55.01% -0.89% -5.83% 6.22% 24.38%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -22.04% 67.38% -25.66% -6.88% -7.39% -10.60% 32.57%
Invested Capital Q/Q Growth		 0.00% 0.00% 29.13% 11.88% 88.51% -15.03% -42.83% 136.68% 1,655.34% 604.06%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -10,358.70% 218.96% -150.79% -5,013.89% 26.76% -47,131.02% 43.44% -52,281.14% -35.26% -920.31%
Operating Margin		 -10,416.60% -1,319.33% -157.69% -5,087.80% 16.14% -49,295.55% 40.82% -56,190.40% -59.95% -1,250.38%
EBIT Margin		 -10,410.12% 201.05% -158.17% -5,126.54% 25.13% -48,408.34% 41.48% -54,298.83% -40.60% -971.93%
Profit (Net Income) Margin		 -10,456.68% -449.30% -166.74% -5,281.08% 23.09% -48,520.86% 41.28% -54,271.70% -41.38% -981.54%
Tax Burden Percent		 100.03% 102.13% 102.63% 100.34% 99.33% 100.23% 99.51% 99.95% 101.92% 100.99%
Interest Burden Percent		 100.42% -218.82% 102.72% 102.67% 92.49% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.67% 0.00% 0.49% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,444.29% -160.45% -303.26%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,435.86% -160.58% -301.05%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,413.87% 152.28% 284.06%
Return on Equity (ROE)		 -72.97% -17.30% -32.50% -56.89% 10.04% -26.80% 18.59% -30.42% -8.17% -19.20%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,599.81% -3,347.07% -345.97% -155.73%
Operating Return on Assets (OROA)		 -16.13% 4.12% -21.04% -42.13% 9.36% -24.05% 16.57% -26.05% -6.74% -16.22%
Return on Assets (ROA)		 -16.20% -9.20% -22.18% -43.40% 8.59% -24.10% 16.49% -26.03% -6.87% -16.38%
Return on Common Equity (ROCE)		 59.98% -13.14% -32.50% -56.89% 10.04% -26.80% 18.59% -30.42% -8.17% -19.20%
Return on Equity Simple (ROE_SIMPLE)		 88.77% -9.96% -36.39% -42.07% 7.12% -20.96% 15.74% -34.67% -8.16% -18.96%
Net Operating Profit after Tax (NOPAT)		 -18 -48 -45 -111 46 -248 372 -471 -156 -327
NOPAT Margin		 -7,291.62% -923.53% -110.38% -3,561.46% 16.03% -34,506.88% 40.62% -39,333.28% -41.97% -875.26%
Net Nonoperating Expense Percent (NNEP)		 -13.21% 11.21% -8.23% -15.36% 2.92% -7.65% 0.29% -8.43% 0.12% -2.20%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -25.12% -8.27% -16.90%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 5,426.32% 601.39% 87.43% 1,545.90% 21.92% 11,925.87% 10.90% 8,552.92% 20.52% 195.58%
R&D to Revenue		 5,090.28% 817.93% 170.26% 3,641.90% 61.94% 30,790.26% 37.22% 38,534.64% 104.34% 859.34%
Operating Expenses to Revenue		 10,516.60% 1,419.33% 257.69% 5,187.80% 83.86% 49,395.55% 59.18% 56,290.40% 159.95% 1,350.38%
Earnings before Interest and Taxes (EBIT)		 -26 10 -65 -160 73 -348 380 -651 -151 -363
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -26 11 -62 -157 77 -339 397 -626 -131 -343
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 3.46 5.13 3.78 3.58 6.50 2.42 1.70 2.64 1.74
Price to Tangible Book Value (P/TBV)		 0.00 3.47 5.14 3.78 3.58 6.50 2.42 1.70 2.64 1.74
Price to Revenue (P/Rev)		 0.00 156.18 23.49 474.62 11.61 15,045.33 6.34 2,656.64 13.40 90.03
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 50.28 0.00 15.56 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 1.99% 0.00% 6.43% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 168.22 186.92 17.51 51.52
Enterprise Value to Revenue (EV/Rev)		 0.00 95.08 17.64 328.44 8.35 12,694.38 3.74 1,097.00 8.83 39.01
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 43.43 0.00 0.00 31.21 0.00 8.60 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 47.29 0.00 0.00 33.23 0.00 9.01 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 52.09 0.00 9.20 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 42.67 0.00 6.35 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 10.52 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 1.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -3.34 -1.63 -1.33 -1.21 -1.05 -1.01 -1.00 -0.99 -0.95 -0.94
Leverage Ratio		 4.50 1.88 1.47 1.31 1.17 1.11 1.13 1.17 1.19 1.17
Compound Leverage Factor		 4.52 -4.11 1.50 1.35 1.08 1.11 1.13 1.17 1.19 1.17
Debt to Total Capital		 51.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 51.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 87.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -39.46% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -1.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 4.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -1.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -2.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 6.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -2.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 5.24 6.67 8.36 17.09 39.64 11.56 4.64 8.89 6.12
Noncontrolling Interest Sharing Ratio		 182.20% 24.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 15.44 14.56 17.12 16.81 17.29 18.21 20.17 15.30 17.54 22.07
Quick Ratio		 15.39 14.49 16.70 16.46 16.53 17.93 19.85 14.99 17.41 21.97
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 65 -45 -76 -102 -14 -226 325 -458 -336 -168
Operating Cash Flow to CapEx		 5,149.74% -1,752.65% -897.02% -3,470.57% 847.95% -1,298.43% 659.66% -1,333.07% -2,749.47% -7,510.47%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.02 0.13 0.01 0.37 0.00 0.40 0.00 0.17 0.02
Accounts Receivable Turnover		 0.73 2.95 14.18 2.30 3,097.22 5.92 4,075.56 0.00 0.00 0.33
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.19 0.46 2.06 0.17 11.62 0.02 10.18 0.01 2.35 0.26
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 500.95 123.55 25.74 158.55 0.12 61.68 0.09 0.00 0.00 1,100.46
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 500.95 123.55 25.74 158.55 0.12 61.68 0.09 0.00 0.00 1,100.46
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -83 -86 -55 -64 -4.35 -26 20 7.03 187 28
Invested Capital Turnover		 -0.01 -0.06 -0.58 -0.05 -8.42 -0.05 -317.25 0.09 3.82 0.35
Increase / (Decrease) in Invested Capital		 -83 -2.90 31 -9.37 60 -22 46 -13 180 -159
Enterprise Value (EV)		 0.00 491 723 1,026 2,418 9,127 3,420 1,314 3,277 1,456
Market Capitalization		 0.00 807 963 1,483 3,362 10,818 5,799 3,183 4,972 3,360
Book Value per Share		 ($5.78) $5.85 $4.58 $7.56 $17.02 $23.56 $31.35 $23.95 $23.70 $22.64
Tangible Book Value per Share		 ($5.87) $5.84 $4.57 $7.55 $17.01 $23.55 $31.35 $23.95 $23.70 $22.64
Total Capital		 74 233 188 392 939 1,664 2,399 1,875 1,883 1,932
Total Debt		 38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -118 -316 -240 -457 -944 -1,690 -2,379 -1,868 -1,696 -1,904
Capital Expenditures (CapEx)		 1.15 3.02 7.81 2.77 6.68 18 82 37 9.47 1.90
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.28 -17 -5.88 -18 -13 -68 -81 -83 106 -54
Debt-free Net Working Capital (DFNWC)		 147 298 234 439 930 1,622 2,298 1,732 1,799 1,849
Net Working Capital (NWC)		 147 298 234 439 930 1,622 2,298 1,732 1,799 1,849
Net Nonoperating Expense (NNE)		 7.82 -24 23 54 -20 101 -5.97 179 -2.17 40
Net Nonoperating Obligations (NNO)		 -118 -319 -243 -457 -944 -1,690 -2,379 -1,868 -1,696 -1,904
Total Depreciation and Amortization (D&A)		 0.13 0.93 3.02 3.52 4.73 9.18 18 24 20 19
Debt-free, Cash-free Net Working Capital to Revenue		 -3,755.47% -335.59% -14.35% -576.18% -4.60% -9,453.69% -8.91% -6,961.52% 28.45% -145.99%
Debt-free Net Working Capital to Revenue		 59,386.64% 5,774.40% 570.47% 14,041.26% 321.30% 225,641.31% 251.12% 144,567.53% 484.71% 4,956.18%
Net Working Capital to Revenue		 59,386.64% 5,774.40% 570.47% 14,041.26% 321.30% 225,641.31% 251.12% 144,567.53% 484.71% 4,956.18%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $1.23 ($5.29) $4.97 ($8.36) ($1.94) ($4.34)
Adjusted Weighted Average Basic Shares Outstanding		 5.04M 39.81M 46.98M 52.28M 54.39M 65.95M 75.95M 77.75M 79.22M 84.36M
Adjusted Diluted Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $1.17 ($5.29) $4.70 ($8.36) ($1.94) ($4.34)
Adjusted Weighted Average Diluted Shares Outstanding		 5.04M 39.81M 46.98M 52.28M 56.93M 65.95M 80.39M 77.75M 79.22M 84.36M
Adjusted Basic & Diluted Earnings per Share		 ($5.06) ($1.89) ($1.71) ($3.44) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.04M 12.26M 40.06M 47.96M 60.85M 75.43M 77.07M 78.65M 80.28M 85.77M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -48 -45 -111 46 -248 372 -471 -156 -327
Normalized NOPAT Margin		 -7,291.62% -923.53% -110.38% -3,561.46% 16.03% -34,506.88% 40.62% -39,333.28% -41.97% -875.26%
Pre Tax Income Margin		 -10,453.85% -439.93% -162.47% -5,263.38% 23.24% -48,408.34% 41.48% -54,298.83% -40.60% -971.93%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.43% -7.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for CRISPR Therapeutics

This table displays calculated financial ratios and metrics derived from CRISPR Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -88.59% -99.95% 10,538.30% 44,203.80% -100.00% 3,353,333.33% -99.50% -99.26% 0.00% -82.26%
EBITDA Growth		 -38.95% 16.78% 72.46% 58.33% 37.21% 182.73% -137.79% -67.38% 24.80% -133.63%
EBIT Growth		 -37.09% 16.34% 70.53% 57.26% 36.19% 174.62% -123.92% -62.88% 23.87% -140.87%
NOPAT Growth		 -41.55% 9.72% 63.35% 48.04% 27.40% 175.37% -118.01% -58.85% 16.83% -165.15%
Net Income Growth		 -37.27% 21.72% 70.39% 58.17% 35.75% 180.80% -119.71% -62.60% 23.37% -141.76%
EPS Growth		 -34.13% 10.26% 71.12% 59.17% 37.05% 180.00% -113.43% -52.04% 28.37% -136.61%
Operating Cash Flow Growth		 -29.37% -31.72% 106.51% 6.14% 62.12% 15.23% 1,147.32% 28.27% -168.25% 47.92%
Free Cash Flow Firm Growth		 50.86% 46.92% 108.88% 29.35% -36.86% -40.53% -930.14% 66.55% 6.70% 202.68%
Invested Capital Growth		 -153.90% -65.42% -246.24% 151.60% 37.23% 2,561.61% 30.08% -174.11% 133.35% -84.90%
Revenue Q/Q Growth		 -40.51% -93.62% 1,666,566.67% -30.00% -100.00% 0.00% -99.75% 2.58% 16.44% 5,828.74%
EBITDA Q/Q Growth		 1.36% 32.86% 59.11% -53.89% -48.65% 188.45% -217.52% -8.32% 33.21% 60.45%
EBIT Q/Q Growth		 2.56% 31.45% 56.90% -48.45% -45.46% 180.17% -229.34% -7.99% 32.01% 56.96%
NOPAT Q/Q Growth		 0.48% 27.88% 50.98% -47.66% -39.05% 174.88% -241.80% -7.59% 27.19% 41.35%
Net Income Q/Q Growth		 6.07% 36.65% 52.01% -46.50% -44.27% 179.67% -230.49% -8.42% 32.01% 56.59%
EPS Q/Q Growth		 6.67% 37.50% 52.14% -46.27% -43.88% 179.43% -227.68% -4.20% 32.21% 59.41%
Operating Cash Flow Q/Q Growth		 25.88% -7.71% 107.76% -1,614.32% 70.09% -141.05% 214.24% -187.09% -11.85% 53.20%
Free Cash Flow Firm Q/Q Growth		 44.33% -8.00% 116.64% -806.28% -7.82% -10.90% 1.71% 71.54% -200.71% 222.05%
Invested Capital Q/Q Growth		 -212.09% 136.68% -592.02% 224.37% -127.97% 1,655.34% -112.93% -31.82% 112.59% 604.06%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -180,963.83% -1,903,416.67% -46.69% -102.65% 0.00% 46.96% -22,030.56% -23,264.22% -13,343.36% -89.01%
Operating Margin		 -194,029.79% -2,192,350.00% -64.49% -136.03% 0.00% 34.58% -27,894.25% -29,257.25% -18,294.02% -180.97%
EBIT Margin		 -186,302.13% -2,000,850.00% -51.75% -109.74% 0.00% 44.52% -22,989.48% -24,201.35% -14,130.56% -102.58%
Profit (Net Income) Margin		 -185,690.43% -1,842,916.67% -53.07% -111.06% 0.00% 44.41% -23,133.13% -24,450.29% -14,276.08% -104.54%
Tax Burden Percent		 99.67% 92.11% 102.55% 101.20% 100.37% 99.74% 100.62% 101.03% 101.03% 101.91%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.26% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -233,467.72% -134,383.80% 0.00% -538.80% 0.00% 131.89% 0.00% -743,692.69% 0.00% -43.89%
ROIC Less NNEP Spread (ROIC-NNEP)		 -233,465.61% -134,382.92% 0.00% -538.22% 0.00% 130.77% 0.00% -743,691.61% 0.00% -44.33%
Return on Net Nonoperating Assets (RNNOA)		 232,608.71% 133,522.80% 0.00% 529.94% 0.00% -124.01% 0.00% 741,510.07% 0.00% 41.83%
Return on Equity (ROE)		 -859.01% -861.00% -25.56% -8.86% -19.20% 7.88% -11.03% -2,182.62% -13.07% -2.06%
Cash Return on Invested Capital (CROIC)		 0.00% -3,347.07% 0.00% -1,189.11% 0.00% -345.97% 0.00% 0.00% -6,197.88% -155.73%
Operating Return on Assets (OROA)		 -1,014.55% -959.78% -2.14% -8.01% 0.00% 7.39% -2,667.51% -2,157.51% -1,319.88% -1.71%
Return on Assets (ROA)		 -1,011.22% -884.02% -2.19% -8.11% 0.00% 7.37% -2,684.17% -2,179.70% -1,333.47% -1.74%
Return on Common Equity (ROCE)		 -859.01% -861.00% -25.56% -8.86% -19.20% 7.88% -11.03% -2,182.62% -13.07% -2.06%
Return on Equity Simple (ROE_SIMPLE)		 -34.84% 0.00% -28.25% -22.90% -20.46% 0.00% -10.42% -13.42% -12.35% 0.00%
Net Operating Profit after Tax (NOPAT)		 -128 -92 -45 -67 -93 69 -98 -106 -77 -45
NOPAT Margin		 -135,820.85% -1,534,645.00% -45.14% -95.22% 0.00% 34.49% -19,525.97% -20,480.08% -12,805.81% -126.68%
Net Nonoperating Expense Percent (NNEP)		 -2.11% -0.87% -0.39% -0.58% -1.05% 1.12% -0.91% -1.08% -0.48% 0.44%
Return On Investment Capital (ROIC_SIMPLE)		 - -4.91% - - - 3.69% - - - -2.34%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 28,724.47% 352,816.67% 22.36% 27.19% 0.00% 8.19% 3,562.10% 3,768.09% 2,893.52% 50.78%
R&D to Revenue		 124,065.96% 1,725,916.67% 99.94% 145.08% 0.00% 47.29% 15,113.49% 15,505.80% 13,647.84% 230.19%
Operating Expenses to Revenue		 194,129.79% 2,192,450.00% 164.49% 236.03% 0.00% 65.42% 27,994.25% 29,357.25% 18,394.02% 280.97%
Earnings before Interest and Taxes (EBIT)		 -175 -120 -52 -77 -112 90 -116 -125 -85 -37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -170 -114 -47 -72 -107 94 -111 -120 -80 -32
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.61 1.70 1.92 2.44 2.09 2.64 2.60 2.32 2.06 1.74
Price to Tangible Book Value (P/TBV)		 2.61 1.70 1.92 2.44 2.09 2.64 2.60 2.32 2.06 1.74
Price to Revenue (P/Rev)		 361.78 2,656.64 35.48 26.05 21.20 13.40 19.93 22.68 19.73 90.03
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 186.92 0.00 61.79 0.00 17.51 0.00 0.00 514.72 51.52
Enterprise Value to Revenue (EV/Rev)		 221.76 1,097.00 16.63 15.63 10.97 8.83 12.17 12.73 10.18 39.01
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -0.99 -1.00 -0.98 -1.01 -0.95 -1.01 -1.00 -1.00 -0.94
Leverage Ratio		 1.16 1.17 1.18 1.19 1.21 1.19 1.19 1.19 1.18 1.17
Compound Leverage Factor		 1.16 1.17 1.18 1.19 1.21 1.19 1.19 1.19 1.18 1.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.89 5.42 5.83 7.26 6.15 9.24 9.45 7.80 7.71 6.60
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 12.81 15.30 13.00 14.00 15.83 17.54 17.81 15.73 21.64 22.07
Quick Ratio		 12.57 14.99 12.83 13.84 15.64 17.41 17.72 15.66 21.55 21.97
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -73 -79 13 -93 -100 -111 -109 -31 -93 114
Operating Cash Flow to CapEx		 -1,748.68% -1,830.53% 287.64% -3,748.10% -1,881.78% -13,018.02% 15,222.19% -13,519.38% -48,818.72% -19,697.24%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.01 0.00 0.04 0.07 0.08 0.17 0.12 0.09 0.09 0.02
Accounts Receivable Turnover		 140.21 0.00 0.00 4.86 0.00 0.00 0.00 0.00 0.00 0.33
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.10 0.01 0.63 1.05 1.06 2.35 1.76 1.34 1.38 0.26
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 2.60 0.00 0.00 75.17 0.00 0.00 0.00 0.00 0.00 1,100.46
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 2.60 0.00 0.00 75.17 0.00 0.00 0.00 0.00 0.00 1,100.46
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -19 7.03 -35 43 -12 187 -24 -32 4.01 28
Invested Capital Turnover		 1.72 0.09 -18.33 5.66 -10.90 3.82 -9.24 36.31 -50.59 0.35
Increase / (Decrease) in Invested Capital		 -55 -13 -58 26 7.14 180 10 -75 16 -159
Enterprise Value (EV)		 3,125 1,314 1,668 2,658 1,865 3,277 3,306 2,574 2,066 1,456
Market Capitalization		 5,098 3,183 3,557 4,431 3,604 4,972 5,414 4,586 4,001 3,360
Book Value per Share		 $25.05 $23.95 $23.59 $23.01 $21.76 $23.70 $25.48 $23.33 $22.77 $22.64
Tangible Book Value per Share		 $25.05 $23.95 $23.58 $23.01 $21.76 $23.70 $25.48 $23.33 $22.77 $22.64
Total Capital		 1,954 1,875 1,855 1,816 1,728 1,883 2,084 1,981 1,940 1,932
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,973 -1,868 -1,889 -1,773 -1,740 -1,696 -2,108 -2,013 -1,936 -1,904
Capital Expenditures (CapEx)		 6.02 6.19 3.06 3.56 2.12 0.74 0.72 0.71 0.22 0.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -114 -83 -122 -41 -90 106 -107 -119 -82 -54
Debt-free Net Working Capital (DFNWC)		 1,782 1,732 1,761 1,727 1,649 1,799 2,001 1,883 1,854 1,849
Net Working Capital (NWC)		 1,782 1,732 1,761 1,727 1,649 1,799 2,001 1,883 1,854 1,849
Net Nonoperating Expense (NNE)		 47 18 7.92 11 19 -20 18 21 8.85 -7.90
Net Nonoperating Obligations (NNO)		 -1,973 -1,868 -1,889 -1,773 -1,740 -1,696 -2,108 -2,013 -1,936 -1,904
Total Depreciation and Amortization (D&A)		 5.02 5.85 5.05 4.96 4.93 4.90 4.83 4.85 4.74 4.84
Debt-free, Cash-free Net Working Capital to Revenue		 -810.03% -6,961.52% -121.68% -24.32% -53.22% 28.45% -39.56% -58.86% -40.21% -145.99%
Debt-free Net Working Capital to Revenue		 12,645.18% 144,567.53% 1,756.64% 1,015.13% 970.17% 484.71% 736.31% 930.93% 914.11% 4,956.18%
Net Working Capital to Revenue		 12,645.18% 144,567.53% 1,756.64% 1,015.13% 970.17% 484.71% 736.31% 930.93% 914.11% 4,956.18%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.24) ($1.40) ($0.67) ($0.98) ($1.41) $1.12 ($1.43) ($1.49) ($1.01) ($0.41)
Adjusted Weighted Average Basic Shares Outstanding		 78.02M 77.75M 78.68M 79.09M 79.41M 79.22M 81.79M 84.92M 85.23M 84.36M
Adjusted Diluted Earnings per Share		 ($2.24) ($1.40) ($0.67) ($0.98) ($1.41) $1.12 ($1.43) ($1.49) ($1.01) ($0.41)
Adjusted Weighted Average Diluted Shares Outstanding		 78.02M 77.75M 78.68M 79.09M 79.41M 79.22M 81.79M 84.92M 85.23M 84.36M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 78.29M 78.65M 78.94M 79.41M 79.43M 80.28M 84.92M 85.17M 85.35M 85.77M
Normalized Net Operating Profit after Tax (NOPAT)		 -128 -92 -45 -67 -93 69 -98 -106 -77 -45
Normalized NOPAT Margin		 -135,820.85% -1,534,645.00% -45.14% -95.22% 0.00% 34.49% -19,525.97% -20,480.08% -12,805.81% -126.68%
Pre Tax Income Margin		 -186,302.13% -2,000,850.00% -51.75% -109.74% 0.00% 44.52% -22,989.48% -24,201.35% -14,130.56% -102.58%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About CRISPR Therapeutics' Financials

When does CRISPR Therapeutics's fiscal year end?

According to the most recent income statement we have on file, CRISPR Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has CRISPR Therapeutics' net income changed over the last 9 years?

CRISPR Therapeutics' net income appears to be on an upward trend, with a most recent value of -$366.25 million in 2024, rising from -$25.83 million in 2015. The previous period was -$153.61 million in 2023. See CRISPR Therapeutics' forecast for analyst expectations on what’s next for the company.

What is CRISPR Therapeutics's operating income?
CRISPR Therapeutics's total operating income in 2024 was -$466.57 million, based on the following breakdown:
  • Total Gross Profit: $37.31 million
  • Total Operating Expenses: $503.88 million
How has CRISPR Therapeutics revenue changed over the last 9 years?

Over the last 9 years, CRISPR Therapeutics' total revenue changed from $247 thousand in 2015 to $37.31 million in 2024, a change of 15,006.9%.

How much debt does CRISPR Therapeutics have?

CRISPR Therapeutics' total liabilities were at $309.95 million at the end of 2024, a 10.6% decrease from 2023, and a 149.9% increase since 2015.

How much cash does CRISPR Therapeutics have?

In the past 9 years, CRISPR Therapeutics' cash and equivalents has ranged from $155.96 million in 2015 to $1.17 billion in 2020, and is currently $298.26 million as of their latest financial filing in 2024.

How has CRISPR Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, CRISPR Therapeutics' book value per share changed from -5.78 in 2015 to 22.64 in 2024, a change of -491.9%.


Related Companies

This page (NASDAQ:CRSP) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
Most traders are panicking. We’re cashing in
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Musk's warning signal: Prepare before the cascade begins
When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...
InvestorPlace | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored